Polyrizon (PLRZ) has commenced preliminary work related to the Good Manufacturing Practice – GMP – manufacturing process for its PL-14 allergy blocker in preparation for its planned 2025 clinical trial. The company works closely with Eurofins CDMO, having recently entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine. Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material requirements. The trial aims to assess the safety and efficacy of PL-14 as an innovative allergy blocker.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon files to sell 2.42M ordinary shares for holders
- Polyrizon announces publication of patent application for hydrogel nasal tech
- Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs
- Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial
- Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker